TrialSignal transduction and targeted therapy2025

A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.

Ran Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.